# Victor Tong

> Victor Tong is a Series A investor at Decheng Capital backing Biotechnology and Health Care. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Decheng Capital](https://shizune.co/investors/profile/decheng-capital)
- Total investments: 6
- Last investment: Jan 2026
- Lead investor: 67%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/victortong/?originalSubdomain=cn

Victor Tong is a Series A investor at Decheng Capital focused on Biotechnology and Health Care. Victor Tong

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 67% |
| Health Care | 3 | 50% |
| Therapeutics | 3 | 50% |
| Medical | 2 | 33% |
| Life Science | 1 | 17% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 33% |
| Series C | 2 | 33% |
| Series B | 1 | 17% |
| Series D | 1 | 17% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 50% |
| Singapore | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cellares | Cellares develops and operates integrated technologies for automated cell therapy manufacturing and quality control that help biopharmaceutical partners scale development to industrial production. The company’s offerings include the Cell Shuttle platform for end-to-end automation of the cell therapy manufacturing process and the Cell Q platform forautomated quality control, supported by integrated software and consumable cartridges. Cellares positions itself as an Integrated Development and Manufacturing Organization that supports process transfer, scalable production, and regulatory pathways for clinical and commercial programs. Its services enable clients to transition manual processes onto automated systems and expand manufacturing capacity to meet broader patient demand. | $257M | Series D | Jan 28, 2026 |  |
| Aardvark Therapeutics | Aardvark Therapeutics specializes in small molecule therapeutics for obesity and rare genetic metabolic disorders. Aardvark Therapeutics was founded by Tien Lee in 2017. | $85M | Series C | May 09, 2024 |  |
| Cellares | Cellares develops and operates integrated technologies for automated cell therapy manufacturing and quality control that help biopharmaceutical partners scale development to industrial production. The company’s offerings include the Cell Shuttle platform for end-to-end automation of the cell therapy manufacturing process and the Cell Q platform forautomated quality control, supported by integrated software and consumable cartridges. Cellares positions itself as an Integrated Development and Manufacturing Organization that supports process transfer, scalable production, and regulatory pathways for clinical and commercial programs. Its services enable clients to transition manual processes onto automated systems and expand manufacturing capacity to meet broader patient demand. | $255M | Series C | Aug 23, 2023 |  |
| Watchmaker Genomics | Watchmaker Genomics is a biotechnology company that focuses on breakthrough applications for reading, writing, and editing DNA. It combines deep domain expertise in protein engineering with enzyme manufacturing to address the demanding quality, performance, and scale requirements of high-growth genomics applications, enabling clients to improvetheir experiment, assay, and workflow with scalable supply chain solutions that provide molecular-grade enzymes for a range of genomic applications. | $40M | Series A | Jun 02, 2022 |  |
| Cellares | Cellares develops and operates integrated technologies for automated cell therapy manufacturing and quality control that help biopharmaceutical partners scale development to industrial production. The company’s offerings include the Cell Shuttle platform for end-to-end automation of the cell therapy manufacturing process and the Cell Q platform forautomated quality control, supported by integrated software and consumable cartridges. Cellares positions itself as an Integrated Development and Manufacturing Organization that supports process transfer, scalable production, and regulatory pathways for clinical and commercial programs. Its services enable clients to transition manual processes onto automated systems and expand manufacturing capacity to meet broader patient demand. | $82M | Series B | May 05, 2021 |  |
| Hummingbird Bioscience | Hummingbird Bioscience uses systems biology to develop insights into disease biology and applies computationally guided platforms to discover and engineer breakthrough biotherapeutics. The company is pursuing a broad pipeline of first drug candidates across multiple challenging targets with strong biological validation and disease association,including lead assets: HMBD-001, an anti-HER3 antibody, and HMBD-002, an anti-VISTA antibody, for the treatment of cancer. Hummingbird has established strategic collaborations with Cancer Research UK and Amgen, and has been awarded a product development grant from the Cancer Prevention and Research Institute of Texas. |  | Series A | Jul 10, 2019 |  |

6 of 6 investments shown.

## Co-investors
- [Eclipse](https://shizune.co/investors/profile/eclipse-ventures) — VC Fund, 5 deals together
- [8VC](https://shizune.co/investors/profile/8vc) — VC Fund, 2 deals together
- [DFJ Growth](https://shizune.co/investors/profile/dfj-growth) — VC Fund, 2 deals together
- [ARK Investment Management](https://shizune.co/investors/profile/ark-investment-management) — VC Fund, 1 deal together
- [BlackRock](https://shizune.co/investors/profile/blackrock) — VC Fund, 1 deal together
- [Bristol-Myers Squibb](https://shizune.co/investors/profile/bristol-myers-squibb) — VC Fund, 1 deal together

## About Decheng Capital

VC Fund · Menlo Park, United States

Decheng Capital is an investment firm that provides capital and strategic support to life science companies with revolutionary technologies and growth-stage healthcare companies with a strong market presence. It is a group of dedicated professionals with complementary expertise who have outstanding track records of building highly successfulcompanies globally. Founded in 2012, Decheng continues to capitalize on a historic opportunity in the rapid growth of the healthcare industry as well as breakthroughs in life science research. With over $2 billion in capital under management and support from some of the most prestigious LPs in the world, Decheng is poised to deliver superior returns for our investors and create value for our entrepreneur partners.

5 contacts available at Decheng Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Dan Zabrowski | Venture Partner | https://shizune.co/investors/profile/dan-zabrowski |
| Min Cui | Founder and Managing Director | https://shizune.co/investors/profile/min-cui |
| Dayton Misfeldt | Partner | https://shizune.co/investors/profile/dayton-misfeldt |
| Nathan Pliam | Partner | https://shizune.co/investors/profile/nathan-pliam |
| Victor Tong | Partner | https://shizune.co/investors/profile/victor-tong |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Victor Tong invest in?

Victor Tong invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series C stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Victor Tong last invest?

The most recent investment recorded for Victor Tong closed in Jan 2026. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co